TrialJournal for immunotherapy of cancer2021

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.

Lawrence G Lum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.